The MUK five protocol: a phase II randomised, controlled, parallel group, multi-centre trial of carfilzomib, cyclophosphamide and dexamethasone (CCD) vs. cyclophosphamide, bortezomib (Velcade) and dexamethasone (CVD) for first relapse and primary refractory multiple myeloma

BACKGROUND: Multiple myeloma is a plasma cell tumour with an annual incidence in the UK of approximately 40–50 per million i.e. about 4500 new cases per annum. The triple combination cyclophosphamide, bortezomib (Velcade®) and dexamethasone (CVD) is an effective regimen at relapse and has emerged in...

Descripción completa

Detalles Bibliográficos
Autores principales: Brown, Sarah, Hinsley, Samantha, Ballesteros, Mónica, Bourne, Sue, McGarry, Paul, Sherratt, Debbie, Flanagan, Louise, Gregory, Walter, Cavenagh, Jamie, Owen, Roger, Williams, Cathy, Kaiser, Martin, Low, Eric, Yong, Kwee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4869302/
https://www.ncbi.nlm.nih.gov/pubmed/27190631
http://dx.doi.org/10.1186/s12878-016-0053-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4869302/
https://www.ncbi.nlm.nih.gov/pubmed/27190631
http://dx.doi.org/10.1186/s12878-016-0053-9

Ejemplares similares